Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.30 |
| ▸ | PGK2 | P07205 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27311676 | 0.78 | — | — | |
| SCHEMBL7156062 | 0.76 | PTPN1 (0.41) | SMPD1PTPN1PGK1PGK2 | |
| SCHEMBL3623749 | 0.74 | SMPD1 (0.36) | SMPD1 | |
| SCHEMBL2676632 | 0.74 | SMPD1 (0.50) | SMPD1PTPN1 | |
| SCHEMBL8165767 | 0.73 | PTPN1 (0.50) | SMPD1PTPN1PGK1PGK2 | |
| Phosphoric Acid SCHEMBL21408828 | 0.71 | TSHR (0.43) | SMPD1PTPN1PGK1PGK2 | |
| SCHEMBL60413 | 0.71 | LMNA (0.39) | SMPD1 | |
| SCHEMBL210519 | 0.71 | SMPD1 (0.57) | SMPD1PTPN1 | |
| SCHEMBL60462 | 0.71 | MPI (0.44) | SMPD1PTPN1PGK1PGK2 | |
| SCHEMBL11299604 | 0.71 | SMPD1 (0.34) | SMPD1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101568-B2 | Methods and compositions for treating solid tumors | GUILFORD PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1185249-B1 | Use of a biodegradable polymer | GUILFORD PHARM INC (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20030203033-A1 | Methods and compositions for treating solid tumors | EISAI INC. | 2003-10-30 | — | — | US | disclosed |
| US-6537585-B1 | Methods and compositions for treating solid tumors | GUILFORD PHARMACEUTICALS, INC. | 2003-03-25 | — | — | US | disclosed |
| EP-1185249-A2 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000057852-A2 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS | GUILFORD PHARMACEUTICALS, INC. (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203033-A1 | Methods and compositions for treating solid tumors | MKI67, TP53, POLI | SMPD1 1140/4885PTPN1 2238/4885PGK1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.